Gene · 3535
Papers1,872
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,872
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data. | Front Immunol | 2023 | 37143670 | PubTator, text mining | PubMed |
| Circulating biosignatures in multiple myeloma and their role in multidrug resistance. | Mol Cancer | 2023 | 37120508 | PubTator, text mining | PubMed |
| Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults. | Nat Aging | 2023 | 37117789 | PubTator, text mining | PubMed |
| Adaptive immune receptor genotyping using the corecount program. | Front Immunol | 2023 | 37114042 | PubTator, text mining | PubMed |
| Improvement of diagnosis in children with Burkitt lymphoma in Kenya: feasibility study for the implementation of fluorescence in situ hybridisation testing for MYC and the MYC/IGH translocation. | Ecancermedicalscience | 2023 | 37113725 | PubTator, text mining | PubMed |
| Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. | Nat Commun | 2023 | 37105962 | PubTator, text mining | PubMed |
| Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity. | Nat Genet | 2023 | 37095364 | PubTator, text mining | PubMed |
| Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. | Front Oncol | 2023 | 37091144 | PubTator, text mining | PubMed |
| Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies. | EMBO Mol Med | 2023 | 37082831 | PubTator, text mining | PubMed |
| IRF4 rearrangement may predict favorable prognosis in children and young adults with primary head and neck large B-cell lymphoma. | Cancer Med | 2023 | 37081786 | PubTator, text mining | PubMed |
| Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. | Nat Commun | 2023 | 37069158 | PubTator, text mining | PubMed |
| Case report: Identification of atypical mantle cell lymphoma with CCND3 rearrangement by next-generation sequencing. | Front Oncol | 2023 | 37064110 | PubTator, text mining | PubMed |
| The main protease of SARS-CoV-2 downregulates innate immunity via a translational repression. | Signal Transduct Target Ther | 2023 | 37055405 | PubTator, text mining | PubMed |
| Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. | Commun Biol | 2023 | 37041231 | PubTator, text mining | PubMed |
| Convergent antibody responses are associated with broad neutralization of hepatitis C virus. | Front Immunol | 2023 | 37033983 | PubTator, text mining | PubMed |
| Clinicopathological analysis of primary thyroid non-Hodgkin lymphoma: a single-center study. | Transl Cancer Res | 2023 | 37033341 | PubTator, text mining | PubMed |
| Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. | Cell Rep | 2023 | 37029928 | PubTator, text mining | PubMed |
| FLAIRR-Seq: A Method for Single-Molecule Resolution of Near Full-Length Antibody H Chain Repertoires. | J Immunol | 2023 | 37027017 | PubTator, text mining | PubMed |
| Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses. | Science | 2023 | 37023193 | PubTator, text mining | PubMed |
| CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring. | Front Oncol | 2023 | 37007084 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3535/papers?page=10